Scholarlink

Background <p>With decreasing sequencing costs and increasingly accurate and scalable methods to interpret genetic variation, genomic newborn screening (gNBS) is being assessed for feasibility, acceptability, and impact worldwide. The field is evolving to determine the genes and variants to report, how to communicate with parents and pediatricians, and confirm results, and how to medically manage children with confirmed diagnoses.</p> Content <p>This review summarizes global gNBS studies, including recruitment methods, consent models, sample types, participant characteristics, sequencing methods, gene selection criteria, test performance, variant interpretation, automated reporting, turnaround time, methods to return results, confirmatory diagnostic testing, and comparisons with standard NBS (stdNBS) results.</p> Summary <p>Early experience supports the feasibility and positive clinical impact of gNBS. Variability in study design, gene selection, and reporting limits direct comparability across studies but increasing and diverse experience will optimize parameters prior to broad implementation.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Genomic newborn screening is feasible and expands the screening of treatable genetic conditions beyond standard newborn screening, and improves the diagnostic accuracy of standard newborn screening.</p> </ItemContent> <ItemContent> <p>Comparison of genomic newborn screening studies around the world, highlighting key differences in study design, technical approaches, clinical implementation, and current challenges.</p> </ItemContent> <ItemContent> <p>Key evidence supporting the implementation of genomic newborn screening is summarized to guide future policy and clinical practice.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Perspectives on genomic newborn screening studies: design, implementation, and outcomes

  • 期刊论文

  • 发表日期：

    2026年7月13日

查看全文
  • Mehmet Bugrahan Duz,
  • Wendy K. Chung

摘要

Background

With decreasing sequencing costs and increasingly accurate and scalable methods to interpret genetic variation, genomic newborn screening (gNBS) is being assessed for feasibility, acceptability, and impact worldwide. The field is evolving to determine the genes and variants to report, how to communicate with parents and pediatricians, and confirm results, and how to medically manage children with confirmed diagnoses.

Content

This review summarizes global gNBS studies, including recruitment methods, consent models, sample types, participant characteristics, sequencing methods, gene selection criteria, test performance, variant interpretation, automated reporting, turnaround time, methods to return results, confirmatory diagnostic testing, and comparisons with standard NBS (stdNBS) results.

Summary

Early experience supports the feasibility and positive clinical impact of gNBS. Variability in study design, gene selection, and reporting limits direct comparability across studies but increasing and diverse experience will optimize parameters prior to broad implementation.

Impact

Genomic newborn screening is feasible and expands the screening of treatable genetic conditions beyond standard newborn screening, and improves the diagnostic accuracy of standard newborn screening.

Comparison of genomic newborn screening studies around the world, highlighting key differences in study design, technical approaches, clinical implementation, and current challenges.

Key evidence supporting the implementation of genomic newborn screening is summarized to guide future policy and clinical practice.